Table 2 The expression of KRT80 in Xuanwei and Non-xuanwei patients and its correlation with clinicopathological parameters.
From: Keratin 80 as a diagnostic biomarker with limited prognostic value in non-small cell lung cancer
Factors | Cases (n) | KRT80 - Xuanwei | P value | Cases (n) | KRT80 - Non-xuanwei | P value | ||
|---|---|---|---|---|---|---|---|---|
Negative | Positive | Negative | Positive | |||||
Gender | Â | Â | Â | 0.521 | Â | Â | Â | 0.683 |
Male | 42 | 8(19.0%) | 34(81.0%) | Â | 65 | 33(50.8%) | 32(49.2%) | Â |
Female | 30 | 4(13.3%) | 26(86.7%) | Â | 38 | 17(44.7%) | 21(55.3%) | Â |
Age(y) | Â | Â | Â | 0.804 | Â | Â | Â | 0.238 |
≤ 60 | 55 | 10(18.2%) | 45(81.8%) |  | 50 | 21(42.0%) | 29(58.0%) |  |
>60 | 17 | 2(11.8%) | 15(88.2%) | Â | 53 | 29(54.7%) | 24(45.3%) | Â |
Smoking history | Â | Â | Â | 0.830 | Â | Â | Â | 0.876 |
Yes | 29 | 4(13.8%) | 25(86.2%) | Â | 42 | 20(47.6%) | 22(52.4%) | Â |
No | 43 | 8(18.6%) | 35(81.4%) | Â | 61 | 30(49.2%) | 31(50.8%) | Â |
Drinking history | Â | Â | Â | 1 | Â | Â | Â | 0.353 |
Yes | 15 | 3(20.0%) | 12(80.0%) | Â | 17 | 10(58.8%) | 7(41.2%) | Â |
No | 57 | 9(15.8%) | 48(84.2%) | Â | 86 | 40(46.5%) | 46(53.5%) | Â |
Differentiation1 | Â | Â | Â | / | Â | Â | Â | 0.796 |
Low | 11 | 5(45.5%) | 6(54.5%) | Â | 12 | 5(41.7%) | 7(58.3%) | Â |
Moderately | 29 | 4(13.8%) | 25(86.2%) | Â | 63 | 29(46.0%) | 34(54.0%) | Â |
High | 8 | 0(0.0%) | 8(100.0%) | Â | 12 | 7(58.3%) | 5(41.7%) | Â |
Unknow | 24 | 3(12.5%) | 21(87.5%) | Â | 16 | 9(56.3%) | 7(43.8%) | Â |
Differentiation2 | Â | Â | Â | 0.032 | Â | Â | Â | 0.734 |
Low | 11 | 5(45.5%) | 6(54.5%) | Â | 12 | 5(41.7%) | 7(58.3%) | Â |
Moderately-High | 37 | 4(10.8%) | 33(89.2%) | Â | 75 | 36(48.0%) | 39(52.0%) | Â |
Unknow | 24 | 3(12.5%) | 21(87.5%) | Â | 16 | 9(56.3%) | 7(43.8%) | Â |
Pathological type | Â | Â | Â | 0.339 | Â | Â | Â | 0.037 |
Squamous Carcinoma | 9 | 3(33.3%) | 6(66.7%) | Â | 35 | 22(62.9%) | 13(37.1%) | Â |
Adenocarcinoma | 63 | 9(14.3%) | 54(85.7%) | Â | 68 | 28(41.2%) | 40(58.8%) | Â |
pT stage1 | Â | Â | Â | 0.286 | Â | Â | Â | / |
T1 | 44 | 9(20.5%) | 35(79.5%) | Â | 50 | 24(48.0%) | 26(52.0%) | Â |
T2 | 19 | 1(5.3%) | 18(94.7%) | Â | 41 | 20(48.8%) | 21(51.2%) | Â |
T3 | 6 | 1(16.7%) | 5(83.3%) | Â | 11 | 5(45.5%) | 6(54.5%) | Â |
T4 | 3 | 1(33.3%) | 2(66.7%) | Â | 1 | 1(100.0%) | 0(0.0%) | Â |
pT stage2 | Â | Â | Â | 0.639 | Â | Â | Â | 1 |
T1-T2 | 63 | 10(15.9%) | 53(84.1%) | Â | 91 | 44(48.4%) | 47(51.6%) | Â |
T3-T4 | 9 | 2(22.2%) | 7(77.8%) | Â | 12 | 6(50.0%) | 6(50.0%) | Â |
Lymph node metastasis(pN stage) | Â | Â | Â | 1 | Â | Â | Â | 0.433 |
Negative | 52 | 9(17.3%) | 43(82.7%) | Â | 51 | 27(52.9%) | 24(47.1%) | Â |
Positive | 20 | 3(15.0%) | 17(85.0%) | Â | 52 | 23(44.2%) | 29(55.8%) | Â |
AJCC stage at diagnosis(pTNM) | Â | Â | Â | 0.737 | Â | Â | Â | 0.365 |
I | 45 | 9(20.0%) | 36(80.0%) | Â | 41 | 23(56.1%) | 18(43.9%) | Â |
II | 12 | 1(8.3%) | 11(91.7%) | Â | 22 | 11(50.0%) | 11(50.0%) | Â |
III | 15 | 2(13.3%) | 13(86.7%) | Â | 40 | 16(40.0%) | 24(60.0%) | Â |
Tumor size(d) | Â | Â | Â | 0.454 | Â | Â | Â | 0.335 |
≤3 cm | 37 | 5(13.5%) | 32(86.5%) |  | 34 | 15(44.1%) | 19(55.9%) |  |
3 < d ≤ 5 cm | 19 | 5(26.3%) | 14(73.7%) |  | 41 | 18(43.9%) | 23(56.1%) |  |
>5 cm | 16 | 2(12.5%) | 14(87.5%) | Â | 26 | 16(61.5%) | 10(38.5%) | Â |
